Abdullah Almeziny, Rahaf Almutairi, Latifah Almehaideb, Renad Almutairi, Amal Altamimi, Khloud Alshehri, Atheer Almutairi, Asem Shadid, Fares Alkhayal, Yasser Alqubaisy
{"title":"Treatment of Cutaneous Warts in Immunocompromised Individuals: A Systematic Review","authors":"Abdullah Almeziny, Rahaf Almutairi, Latifah Almehaideb, Renad Almutairi, Amal Altamimi, Khloud Alshehri, Atheer Almutairi, Asem Shadid, Fares Alkhayal, Yasser Alqubaisy","doi":"10.1002/der2.70039","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>While existing literature focuses on treating warts in immunocompetent persons, there is a lack of comprehensive recommendations for managing cutaneous warts in immunocompromised (ID) patients. The review aimed to appraise the most effective and safe treatment for cutaneous warts in ID patients.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>The systematic review followed (PRISMA) guidelines. The PubMed, Scopus, and Cochrane databases were employed to search for papers published between January 2015 and May 2024.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Two hundred twenty-five studies were found, however this study included 16 studies. Among the reviewed studies, there was one RCT, 11 case reports, and four case series/retrospective cohort studies. Despite the precise pathway of action of various antigens is undetermined, immunotherapies offer a secure and economically feasible method of treating warts. Other frequently employed therapies include cryotherapy and salicylic acid and are generally effective for the management of warts at the area of interest. The majority of the studies analyzed had low RoB when assessed using the ROBINS-E approach.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This review summarised the available literature on the application of immunotherapies for managing resistant warts. It revealed that immunotherapy is a viable treatment for ID people who have not responded to previous medications.</p>\n </section>\n </div>","PeriodicalId":100366,"journal":{"name":"Dermatological Reviews","volume":"6 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/der2.70039","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatological Reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/der2.70039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
While existing literature focuses on treating warts in immunocompetent persons, there is a lack of comprehensive recommendations for managing cutaneous warts in immunocompromised (ID) patients. The review aimed to appraise the most effective and safe treatment for cutaneous warts in ID patients.
Materials and Methods
The systematic review followed (PRISMA) guidelines. The PubMed, Scopus, and Cochrane databases were employed to search for papers published between January 2015 and May 2024.
Results
Two hundred twenty-five studies were found, however this study included 16 studies. Among the reviewed studies, there was one RCT, 11 case reports, and four case series/retrospective cohort studies. Despite the precise pathway of action of various antigens is undetermined, immunotherapies offer a secure and economically feasible method of treating warts. Other frequently employed therapies include cryotherapy and salicylic acid and are generally effective for the management of warts at the area of interest. The majority of the studies analyzed had low RoB when assessed using the ROBINS-E approach.
Conclusion
This review summarised the available literature on the application of immunotherapies for managing resistant warts. It revealed that immunotherapy is a viable treatment for ID people who have not responded to previous medications.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
